Abstract:CNS Neuroscience & TherapeuticsVolume 27, Issue 12 p. 1610-1613 LETTER TO THE EDITOROpen Access Taste loss as the sole presenting symptom in Chinese patient with facial onset sensory and motor neuronopathy Lu-Xi Chen, Lu-Xi Chen Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorGong-Lu Liu, Gong-Lu Liu Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorHao Yu, Hao Yu Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorZhi-Ying Wu, Zhi-Ying Wu orcid.org/0000-0003-2106-572X Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorHong-Fu Li, Corresponding Author Hong-Fu Li hongfuli@zju.edu.cn orcid.org/0000-0002-2203-0046 Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China Correspondence Hong-Fu Li, Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China. Email: hongfuli@zju.edu.cnSearch for more papers by this author Lu-Xi Chen, Lu-Xi Chen Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorGong-Lu Liu, Gong-Lu Liu Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorHao Yu, Hao Yu Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorZhi-Ying Wu, Zhi-Ying Wu orcid.org/0000-0003-2106-572X Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorHong-Fu Li, Corresponding Author Hong-Fu Li hongfuli@zju.edu.cn orcid.org/0000-0002-2203-0046 Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China Correspondence Hong-Fu Li, Department of Neurology and Research Center of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China. Email: hongfuli@zju.edu.cnSearch for more papers by this author First published: 02 November 2021 https://doi.org/10.1111/cns.13755AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat Dear Editors, First reported by Vucic in 2006,1 facial onset sensory and motor neuronopathy (FOSMN) syndrome is a rare progressive neurological disease, with a total of 100 patients reported in the literatures worldwide.2 However, no cases have been reported from Chinese centers. The age of onset is usually during the fourth to seventh decade with only one case of childhood onset reported.3 There is a male predominance, with nearly two-thirds of cases seen in men, and the disease duration ranges from 1.2 to 46 years with an average duration of 8.2 years.2 Patients of FOSMN initially present with sensory deficits of the trigeminal nerve distribution, followed by rostral-caudal spreading to the scalp, neck, upper trunk, and upper limbs.1 Later in the course of the disease, bulbar dysfunction (dysarthria and dysphagia) occurs. Then, lower motor neuron (LMN) features present, including muscle weakness, atrophy, and fasciculation. Generally, only the lower motor neuron system is involved, while the upper motor neuron involvement is rarely seen.4 Herein, we described a Chinese patient with FOSMN who initially presented with taste disturbance. 1 CASE PRESENTATION A 72-year-old Chinese man presented to our neurology clinic complaining of progressive loss of taste over 2 years. He was unable to differentiate spicy, salty, or sweet tastes. One month after the onset, he noticed constant tingling and numbness at the tip of his tongue and pain in the peri-oral region, which disrupted his sleep. He was prescribed gabapentin, and the pain was relieved. One year later, he exhibited paresthesia in his right upper limb, followed by muscle atrophy. At the same time, he developed sialorrhea and headache. One and a half years after initial presentation, he developed dysphagia, hearing impairment, and hyposmia. In the latest 2 months, his dysphagia deteriorated, and he developed dysarthria with losing 5 kilograms of weight. The total timeline of symptom onset is shown in Figure 1A. He sought his medical care in the local hospital and was diagnosed with "progressive bulbar palsy." His family history was unremarkable. FIGURE 1Open in figure viewerPowerPoint Clinical history and cranial nerves examinations of FOSMN patient. (A) The onset timeline of symptoms in the FOSMN patient. (B) Absent bilateral corneal reflexes. (C) Atrophy of the bilateral temporal and masseter muscles Cranial nerves examinations revealed absent corneal reflexes (Figure 1B), reduced gag reflex, and loss of taste sensation in the entire tongue. There was no tongue atrophy or fasciculation. Light touch sensation and pinprick sensation were diminished in the peri-oral distribution and right limb. Vibration and proprioception sensations were normal. Medical Research Council (MRC) grade of neck flexion was 4-. Muscle atrophy was seen in the bilateral temporal and masseter muscles (Figure 1C) and in the right upper limb (deltoid muscle, biceps muscle, and subscapularis muscle). Strength was normal in all limbs. Deep tendon reflexes were normal in the upper limbs, but brisk in lower limbs. Bilateral palmomental reflexes were positive. There was no extrapyramidal dysfunction, cerebellar ataxia, nor dysautonomia. Systemic examination was unremarkable. A Mini-Mental State Examination (MMSE) score was 30 out of 30. The Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) score was 43. Results of complete blood count, creatine kinase, electrolytes, total cholesterol and triglyceride, liver function, renal functions, blood sugar, HbA1c, and C-reactive protein were normal. Nerve conduction study showed sensory nerve action potentials (SNAP) decreased in the right median nerve, ulnar nerve, and both superficial peroneal nerves. In needle electromyography, extensively chronic neurogenic changes were apparent in muscles of the bulbar, cervical, thoracic, and lumbosacral regions. A pulmonary function test showed that his forced vital capacity (FVC) was 59.3%. Magnetic resonance imaging scans of the brainstem showed no abnormality (Figure 2). Genetic testing of the whole exome sequence was negative. Abnormal nucleotides repeat expansions of the AR or C9ORF72 genes were negative. FIGURE 2Open in figure viewerPowerPoint No abnormality found in brainstem (midbrain, pons, and medulla) on MR axial T2 and T2-weighted-Fluid-Attenuated Inversion Recovery (T2-FLAIR) 2 DISCUSSION There have been two cases of FOSMN reported with initially taste disturbances in patients of Caucasian and Japanese descent respectively. The Caucasian patient was a 42-year-old man with taste sensation loss, paresthesia, and numbness in the peri-oral area. However, his numbness did not progress to the head and neck until 5 years later.1 The Japanese patient was a 49-year-old man who presented solely with taste disturbance, and other manifestations developed more than 4 years later.5 Different from these two cases, our Chinese patient with FOSMN presented with only taste loss initially, but developed tongue numbness and peri-oral pain 1 month later. His other symptoms manifested about 1 year later, suggesting more rapid progression in our patient. LMN symptoms are common in patients with FOSMN, while only a few cases also have UMN symptoms.6 Other reports indicate that the development of UMN signs is associated with more rapid disease progression.7 Our case also corroborates this association, with examination finding of UMN signs and a more rapid disease course. Our case met the diagnostic criteria of amyotrophic lateral sclerosis (ALS) according to the revised El Escorial criteria, which may be the reason for initial misdiagnosis. Our case showed no abnormality in magnetic resonance imaging scans of the brainstem. However, recent studies detected neurochemical or glucose-metabolism abnormalities in brain stem and cortex of ALS animals using magnetic resonance spectroscopy, suggesting that the above abnormalities may contribute to early differential diagnosis between patients with ALS and FOSMN.8, 9 It remains controversial whether FOSMN is a neurodegenerative disease, an inflammatory disease, or a mix of pathophysiological mechanisms. Minimal response to immunomodulation therapy with refractory progression suggests that FOSMN probably falls into the neurodegenerative spectrum. In addition, FOSMN patients can carry mutations in SOD1, TARDBP, and SQSTM1,2 indicating a potential overlap between FOSMN and ALS. In addition, TDP43 pathology, which is associated with ALS, was detected in the brainstem and spinal cord of FOSMN cases at autopsy.10 TDP43-positive inclusions were seen in both motor (anterior horn cells) and sensory (dorsal root ganglia) neurons in FOSMN, while sensory neurons were spared in ALS.10 Sensory functions are commonly spared in ALS patients. However, a minority of patients with ALS do have sensory disturbances, including taste change.11 Nevertheless, there have been no reported cases of ALS with taste disorder as the initial manifestation.5 Steroids, immune modulation, and intravenous immunoglobulin have not been effective for most patients with FOSMN. Only three reported patients have benefited, with only one having long-term effect and the other two patients having only transient improvement.2, 12 Considering the controversial therapeutic effects and the definite side effects of steroids, we did not use immunomodulatory therapies in our patients. It has been reported that the combined use of the ALS-targeted drug riluzole and the anti-inflammatory drug celecoxib presented neuroprotection in FUS-tg mice, which may imply the potential benefits in FOSMN.13 To our knowledge, this is the first report of a Chinese patient with FOSMN presenting with taste deficits as the initial symptom, with subsequently presbycusis and hyposmia. More importantly, patients with LMN and UMN signs may mimic ALS at first sight, though the onset of taste disturbance heralds the diagnosis of FOSMN. ACKNOWLEDGEMENTS The authors would like to thank the efforts of Meiying Zhuang for helping revising the language. CONFLICTS OF INTEREST The authors declare that there is no conflict of interest. CONSENT TO PARTICIPATE The patient provided written consent for participation. CONSENT FOR PUBLICATION The patient provided written consent for disclosure of medical information and images. Open Research DATA AVAILABILITY STATEMENT The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding authors. REFERENCES 1Vucic S, Tian D, Chong PS, Cudkowicz ME, Hedley-Whyte ET, Cros D. Facial onset sensory and motor neuronopathy (FOSMN syndrome): a novel syndrome in neurology. Brain. 2006; 129(Pt 12): 3384- 3390. CrossrefCASPubMedWeb of Science®Google Scholar 2de Boer EMJ, Barritt AW, Elamin M, et al. Facial onset sensory and motor neuronopathy: new cases, cognitive changes, and pathophysiology. Neurol Clin Pract. 2021; 11(2): 147- 157. CrossrefPubMedWeb of Science®Google Scholar 3Karakis I, Vucic S, Srinivasan J. Facial onset sensory and motor neuronopathy (FOSMN) of childhood onset. Muscle Nerve. 2014; 50(4): 614- 615. Wiley Online LibraryCASPubMedWeb of Science®Google Scholar 4Vucic S, Stein TD, Hedley-Whyte ET, et al. FOSMN syndrome: novel insight into disease pathophysiology. Neurology. 2012; 79(1): 73- 79. CrossrefCASPubMedWeb of Science®Google Scholar 5Ohashi N, Nonami J, Kodaira M, Yoshida K, Sekijima Y. Taste disorder in facial onset sensory and motor neuronopathy: a case report. BMC Neurol. 2020; 20(1): 71. CrossrefPubMedWeb of Science®Google Scholar 6Ziso B, Williams TL, Walters RJ, et al. Facial onset sensory and motor neuronopathy: further evidence for a TDP-43 proteinopathy. Case Rep Neurol. 2015; 7(1): 95- 100. CrossrefPubMedWeb of Science®Google Scholar 7Zhang Q, Cao B, Chen Y, et al. Facial onset motor and sensory neuronopathy syndrome with a novel TARDBP mutation. Neurologist. 2019; 24(1): 22- 25. CrossrefPubMedWeb of Science®Google Scholar 8Tefera TW, Borges K. Neuronal glucose metabolism is impaired while astrocytic TCA cycling is unaffected at symptomatic stages in the hSOD1(G93A) mouse model of amyotrophic lateral sclerosis. J Cereb Blood Flow Metab. 2019; 39(9): 1710- 1724. CrossrefCASPubMedWeb of Science®Google Scholar 9Lei H, Dirren E, Poitry-Yamate C, Schneider BL, Gruetter R, Aebischer P. Evolution of the neurochemical profiles in the G93A-SOD1 mouse model of amyotrophic lateral sclerosis. J Cereb Blood Flow Metab. 2019; 39(7): 1283- 1298. CrossrefCASPubMedWeb of Science®Google Scholar 10Rossor AM, Jaunmuktane Z, Rossor MN, Hoti G, Reilly MM. TDP43 pathology in the brain, spinal cord, and dorsal root ganglia of a patient with FOSMN. Neurology. 2019; 93(2): e88. Web of Science®Google Scholar 11Tarlarini C, Greco LC, Lizio A, Gerardi F, Sansone VA, Lunetta C. Taste changes in amyotrophic lateral sclerosis and effects on quality of life. Neurol Sci. 2019; 40(2): 399- 404. CrossrefPubMedWeb of Science®Google Scholar 12Knopp M, Vaghela NN, Shanmugam SV, Rajabally YA. Facial onset sensory motor neuronopathy: an immunoglobulin-responsive case. J Clin Neuromuscul Dis. 2013; 14(4): 176- 179. CrossrefPubMedGoogle Scholar 13de Munter J, Shafarevich I, Liundup A, et al. Neuro-cells therapy improves motor outcomes and suppresses inflammation during experimental syndrome of amyotrophic lateral sclerosis in mice. CNS Neurosci Ther. 2020; 26(5): 504- 517. Wiley Online LibraryPubMedWeb of Science®Google Scholar Volume27, Issue12December 2021Pages 1610-1613 FiguresReferencesRelatedInformation

Abstract:CNS Neuroscience & TherapeuticsVolume 24, Issue 12 p. 1305-1308 LETTER TO THE EDITOROpen Access Motor neuron disease-like phenotype associated with anti-IgLON5 disease Qing-Qing Tao, Qing-Qing Tao Department of Neurology and Research Center of Neurology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorQiao Wei, Qiao Wei Department of Neurology and Research Center of Neurology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorShui-Jiang Song, Shui-Jiang Song Department of Neurology and Research Center of Neurology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorXin-Zhen Yin, Corresponding Author Xin-Zhen Yin yinxz@zju.edu.cn orcid.org/0000-0001-9063-4012 Department of Neurology and Research Center of Neurology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Correspondence: Xin-Zhen Yin, MD, PhD, Department of Neurology and Research Center of Neurology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China Email: yinxz@zju.edu.cnSearch for more papers by this author Qing-Qing Tao, Qing-Qing Tao Department of Neurology and Research Center of Neurology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorQiao Wei, Qiao Wei Department of Neurology and Research Center of Neurology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorShui-Jiang Song, Shui-Jiang Song Department of Neurology and Research Center of Neurology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorXin-Zhen Yin, Corresponding Author Xin-Zhen Yin yinxz@zju.edu.cn orcid.org/0000-0001-9063-4012 Department of Neurology and Research Center of Neurology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Correspondence: Xin-Zhen Yin, MD, PhD, Department of Neurology and Research Center of Neurology, Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang 310009, China Email: yinxz@zju.edu.cnSearch for more papers by this author First published: 13 August 2018 https://doi.org/10.1111/cns.13038Citations: 16AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat 1 INTRODUCTION Anti-IgLON5 disease is a novel antibody-mediated disorder characterized by the positive antibody to a neuronal cell adhesion protein named IgLON5 in serum and/or cerebral spinal fluid (CSF).1 Patients with anti-IgLON5 disease developed a characteristic sleep disorder usually accompanied by some other symptoms such as bulbar symptoms, gait abnormalities, oculomotor problems, and cognitive decline.2 Since Lidia et al reported the first anti-IgLON5 disease case in 2014,3 only a few patients have been reported worldwide include 2 patients in Chinese population.4-6 Here, we report the first anti-IgLON5 disease patient with motor neuron disease-like (MND-like) phenotype. 2 CASE REPORT The patient was a 57-year-old male with a chief complaint of progressive dysphagia for 2 y, limb weakness and dyspnea for 5 mo. Mild pharynx and larynx discomfort were noticed at first which then developed to mild dysphagia 2 y ago. The symptoms aggravated progressively during the following 2 y. Slowly limb weakness and rapidly progressed intrinsic hand muscle atrophy were noticed 19 mo after disease onset (Figure 1 A, B). Simultaneously, mild dyspnea developed, which appeared to be more obvious during sleep at night. The wife of the patient complained that her husband had prominent sleep abnormalities with snoring and involuntary movement (Video S1). Having developed transient unconsciousness at night, the patient was admitted to a local hospital 20 mo after disease onset. During the next four mo, recurrent respiratory failure accompanied abnormal behavior and consciousness was noticed. Mechanical ventilation was used to provide respiratory support. After ruling out the possibility of any infectious disease, immunosuppressive therapy was initiated with prednisolone 1000 mg i.v. per d for 3 d, 500 mg i.v. per d for 3 consecutive d and gradually tapered to 80 mg i.v. per d. Intravenous immunoglobulin (IVIg) (0.4 g/Kg i.v. for 5 consecutive d) was also given. The above symptoms slightly improved and spontaneous respiration was recovered. The patient was then referred to our hospital for further diagnosis and treatment. There was no family history of note. Neurological examination revealed a normal mental status and slightly slurred speech. Examinations of the cranial nerves showed bilaterally disappeared pharynx reflex. Muscle weakness involved all his extremities, with a mild decreased strength of all extremities (4/5). Atrophy of bilateral intrinsic hand muscles was observed. Hoffmann and Babinski sign was absent bilaterally. Tendon reflexes were normal in all four extremities. Sensory and cerebellar function was normal. Routine blood test, blood biochemical test, vitamin B12, folate, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and thyroid function were within normal ranges. Serology for HIV, hepatitis, and syphilis were negative as well. Tumor markers examination showed mild elevation of carcinoembryonic antigen with 7.1 ng/mL (normal range < 5.0 ng/mL). Blood gas analysis showed the partial pressure of carbon dioxide was 52.9 mm Hg (normal range < 44.0 mm Hg).The lumbar puncture showed intracranial pressure was 170 mm H2O and CSF analysis showed normal protein, glucose, cell counts, and IgG synthesis rate. No abnormalities were found in brain magnetic resonance imaging (MRI) examination (Figure 1C-F). Electromyography (EMG) test showed extensive denervation in limb muscles and thoracic paraspinal muscles (Table 1). The PSG results showed no obvious obstructive sleep apnea (OSA) events with an apnea-hypopnea index (AHI) of 2.3/h (normal ≤ 5/h). Mean oxygen saturation was 93% with a nadir of 90%. The examination of a group of autoantibodies showed positive anti-IgLON5 antibody in both serum (1:320) and CSF (1:1) with IFT method. (Oumeng, Hangzhou, China) thereby confirming the diagnosis. Antibodies to other cell surface or synaptic proteins including, NMDA, AMPA, GABAB, DPPX, LGI1, and Caspr2 were negative. Additionally, a high association with the HLA-DQB1*05:01 and HLA-DRB1*10:01 alleles was reported previously.7 Thus, human leukocyte antigen (HLA) typing was performed and both of the HLADQB1*0501 and HLA-DRB1*1001 alleles were identified. No specific abnormalities were found in whole body FDG PET/CT scan. Figure 1Open in figure viewerPowerPoint Clinical findings in the patient with anti-IgLON5 disease. Rapidly progressed intrinsic hand muscle atrophy (A-B); Brian MRI showed no abnormal signals nor atrophy (C-F) Table 1. Needle electromyography (EMG) results of the patient Needle EMG results Side Muscle Insertional activity Spontaneous activity Voluntary activity Positive sharp waves Fibrillation Fasciculation Amplitude (mv) Duration (ms) Polyphasics (%) Right Anterior tibial muscle Normal (−) (−) (−) 7.8 14.6 50 Left Medial femoral muscle Normal (−) (−) (−) 5.3 15.1 20 Right First dorsal interosseous muscle Extend (+) (+) (+) 4.2 14.1 50 Left Deltoid Extend (+) (+) (−) 6.5 12.2 30 Right Sternocleidomastoid Extend (+) (+) (−) 1.6 11.5 60 Right Rectus abdominis Normal (−) (−) (−) 2.4 12.3 10 The patient's condition deteriorated 1 month after immunomodulatory therapy. The titer of anti-IgLON5 antibody in serum was assayed again and it decreased to (1:100), indicating that there was no correlation between clinical manifestations and the titer of antibody. To date, only one study reported that a patient has good outcome after immunotherapy using IVIg followed by mycophenolate mofetil 1.5 g/d as a chronic immunotherapy.4 Unfortunately, the patient in our study suffered from suspicious tuberculosis with a positive T-SPOT when we screened for the possible contraindication of chronic immunotherapy. The patient underwent additional plasmapheresis treatments. However, the treatment was not effective. The patient could not maintain spontaneous breathing soon and mechanical ventilation was used to provide respiratory support. 3 DISCUSSION As a relatively novel disease, clinical spectrum of anti-IgLON5 disease has not been fully described and is easy to be ignored if not raise awareness. According to a recent study which analyzed 22 patients with anti-IgLON5 disease, four syndromes have been summarized as the phenotype of the disorder by the time of diagnosis include sleep disorder, bulbar syndrome, progressive supranuclear palsy (PSP-like), and cognitive decline with or without chorea.2 Rare clinical manifestations of the disease still need to be investigated. A recent study reported that peripheral involvement may also occur in anti-IgLON5 disease.8 To the best of our knowledge, this is the first reported patient with anti-IgLON5 disease featured with MND-like phenotype, including progressively dysphagia, limbs weakness with muscles atrophy, and extensive denervation in limb muscles and thoracic paraspinal muscles.9 From the perspective of neuropathology, it is not surprise that MND-like phenotype is associated with anti-IgLON5 disease as neuron-specific tau deposits have been found preferentially involving the hypothalamus, the tegmental nuclei of the brainstem, the upper cervical cord as well as anterior horn of spinal cord.7 The prognosis of the disease appears to be unoptimistic as most patients did not well respond to common immunotherapies and a considerable number of reported patients died from sudden death.2, 10 The patient still could not maintain spontaneous breathing at last follow-up time (2 months). Collectively, the results reported here expanded the known clinical features for this rare disease. In addition, anti-IgLON5 disease should be considered in differential diagnosis of motor neuron disease. CONFLICT OF INTEREST The authors declare no conflict of interest. Supporting Information Filename Description cns13038-sup-0001-VideoS1.mp4application/mp4, 1.4 MB Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Dale RC, Ramanathan S. Cell surface antibody-associated neurodegeneration: The case of anti-IgLON5 antibodies. Neurology. 2017; 88(18): 1688- 1690. 2Gaig C, Graus F, Compta Y, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology. 2017; 88(18): 1736- 1743. 3Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol. 2014; 13(6): 575- 586. 4Haitao R, Yingmai Y, Yan H, et al. Chorea and parkinsonism associated with autoantibodies to IgLON5 and responsive to immunotherapy. J Neuroimmunol. 2016; 300: 9- 10. 5Zhu L, Liu L, Cui S, et al. One case of anti-IgLON5 syndrome. Chin J Neurol. 2017; 10: 763- 765. 6Hasselbacher K, Steffen A, Wandinger KP, Bruggemann N. IgLON5 antibodies are infrequent in patients with isolated sleep apnea. Eur J Neurol. 2018; 25(4): e46– e47. 7Gelpi E, Hoftberger R, Graus F, et al. Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol. 2016; 132(4): 531- 543. 8Wenninger S. Expanding the clinical spectrum of IgLON5-syndrome. J Neuromuscul Dis. 2017; 4(4): 337- 339. 9Bellingham MC. A review of the neural mechanisms of action and clinical efficiency of riluzole in treating amyotrophic lateral sclerosis: what have we learned in the last decade? CNS Neurosci Ther. 2011; 17(1): 4- 31. 10Honorat JA, Komorowski L, Josephs KA, et al. IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol Neuroinflamm. 2017; 4(5): e385. Citing Literature Volume24, Issue12December 2018Pages 1305-1308 FiguresReferencesRelatedInformation

Facial Numbness, Dysarthria, Muscle Atrophy, and Weakness in a Young Patient

Bilateral Facial Nerve (Bell’s) Palsy in a 24-Year-Old Woman: A Case Report

[A 54-year-old man with generalized muscle atrophy and oculomotor paresis]

Taste Loss As the Sole Presenting Symptom in Chinese Patient with Facial Onset Sensory and Motor Neuronopathy

Severe Dysphagia as a Presentation of Parkinson’s Disease

Flail arm syndrome:a benign motor neuron disease manifesting as wasting and weakness of the arms

Acute Mitochondrial Myopathy with Respiratory Insufficiency and Motor Axonal Polyneuropathy.

Preliminary Clinical and Genetic Study of a Family with Ophthalmoplegia, Dysphagia and Facial Weakness

Subclinical spinal muscular atrophy in a 60-year-old man

Oculopharyngeal muscular dystrophy,the clinical,electrophysiologic,myopathological and genetic study in a family

A Madras Motor Neuron Disease Patient with Cerebellar Atrophy: A New Clinical Feature

Heriditary pyramidal tract, corpus callusum and peripheral degeneration, one family report

Pyramidal signs in a Caucasian patient with spinal muscular atrophy: a case report.

[A case of Möbius syndrome with congenital facial palsy and supranuclear oculomotor palsy]

Oculopharyngeal Weakness, Hypophrenia, Deafness, and Impaired Vision

Clinical Reasoning: A 32-Year-Old Man With Painless Bilateral Shoulder Girdle Weakness and Atrophy

Motor Neuron Disease‐like Phenotype Associated with Anti‐iglon5 Disease

Myoclonic Epilepsy with Ragged-Red Fibers: A Case Report

Teaching NeuroImages: Hirayama Disease with Symmetric Atrophy of Bilateral Distal Upper Extremities

Bilateral Facial Palsy Without Ocular Muscle Involvement in Myasthenia Gravis: Case Report.

Juvenile Amyotrophic Lateral Sclerosis: A Case Report of a Rare and Aggressive Presentation in a 22-Year-Old Filipino Male